Share: Facebook Twitter LinkedIn
Activity Provided By:

i3 Health

Virtual Tumor Board: Diagnosis and Management of Myelodysplastic Syndromes

Access Activity

Overview / Abstract:


Myelodysplastic syndromes (MDS) are a group of heterogeneous hematopoietic disorders derived from an abnormal multipotent progenitor cell, characterized by ineffective hematopoiesis, bone marrow failure, and peripheral blood cytopenias. Survival in MDS ranges from a median of 5.3 years in lower-risk patients to as little as 0.8 years in higher-risk patients. Mortality is usually a result of infection, hemorrhage, and/or iron overload secondary to red blood cell transfusions. Approximately 30% of patients with MDS progress to acute myeloid leukemia (AML). The estimated annual age-adjusted incidence of MDS in the United States is 3 to 4 cases per 100,000 individuals, with approximately 14,011 new cases per year. Considering the aging population, the incidence of MDS will likely grow in persons older than 60 years of age.


Hematology/oncology physicians, pathologists, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with MDS.


Upon completion of this activity, participants should be able to:

1.) Assess patient and tumor characteristics that can inform personalized care plans for patients with MDS
2.) Differentiate emerging data and guideline recommendations on therapeutic approaches for lower- risk, higher-risk, and therapy-related MDS
3.) Evaluate supportive care strategies that can help patients with MDS achieve their goals of cancer therapy


May 20, 2021


Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME


Online, Webinar / Webcast / Video

Credits / Hours




Presenters / Authors / Faculty

David P. Steensma, MD, FACP (Chairperson)
Senior Physician
Dana-Farber Cancer Institute

Reza Nejati, MD
Associate Professor, Department of Pathology
TUHS-Fox Chase Cancer Center

Ilene Galinsky, BSN, MSN, ANP-C
Nurse Practitioner
Dana-Farber Cancer Institute

Activity Specialities / Related Topics

Hematology, Pathology, Transplant Medicine

Sponsors / Supporters / Grant Providers

This activity is supported by independent educational grants from Takeda Oncology and Taiho Oncology, Inc.

Keywords / Search Terms

i3 Health i3 Health, multiple myeloma, MM, online CNE, free CNE, free CE CME, free CE CME, free CE CME, NCPD, free NCPD, online NCPD, online NCPD CME, free CE CME Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map